The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma

SIMPLE SUMMARY: The EZH2-targeted drugs have demonstrated notable therapeutic effects in EZH2 mutant B-cell lymphoma patients. In this study, we demonstrated that the combination of EZH2 inhibitor SHR2554 and HDAC inhibitor HBI8000 exert synergistic anti-proliferative activity in both EZH2 wide-type...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xing, Wang, Dedao, Ding, Ning, Mi, Lan, Yu, Hui, Wu, Meng, Feng, Feier, Hu, Luni, Zhang, Yime, Zhong, Chao, Ye, Yingying, Li, Jiao, Fang, Wei, Shi, Yunfei, Deng, Lijuan, Ying, Zhitao, Song, Yuqin, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428225/
https://www.ncbi.nlm.nih.gov/pubmed/34503063
http://dx.doi.org/10.3390/cancers13174249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428225/
https://www.ncbi.nlm.nih.gov/pubmed/34503063
http://dx.doi.org/10.3390/cancers13174249

Ejemplares similares